Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
premenopausal
•
mammaprint
•
pt3
Would a low genomic Mammaprint score deter you from offering adjuvant chemotherapy to a premenopausal woman with pT3N0 breast cancer?
Related Questions
How would you manage a young premenopausal woman with hormone receptor-positive micrometastatic breast cancer in two axillary lymph nodes, but with only DCIS on breast surgical pathology?
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
Would history of breast cancer deter you from using ospemifene for severe vaginal dryness/dyspareunia?
What recommendations would you make for a patient on long-term phenytoin due to epilepsy with a newly diagnosed breast cancer requiring doxorubicin as part of her chemotherapy?
Does delay to the time of lumpectomy impact your decision to omit radiation?
Would you offer adjuvant chemotherapy for triple negative invasive papillary carcinoma of breast?
Is there data to support the substitution of docetaxel with nab-paclitaxel in the TCHP neoadjuvant regimen in the event of hypersensitivity?
Would you consider offering adjuvant Olaparib to a patient with early stage triple negative breast cancer, cT3N0, ypT1aN0, with BRCA VUS who has residual disease after neoadjuvant KEYNOTE-522 regimen?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
In patients with ATM heterozygous mutation, do you prefer aromatase inhibitor over tamoxifen for adjuvant endocrine therapy?
